최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of Korean academy of nursing = 대한간호학회지, v.45 no.1, 2015년, pp.118 - 128
박진희 (아주대학교 간호대학) , 배선형 (동아대학교 간호학과) , 정용식 (아주대학교 의과대학) , 정영미 (아주대학교 간호대학)
Purpose: Evidence suggests that some patients with breast cancer experience cognitive difficulties following chemotherapy. This longitudinal study was done to examine the prevalence of cognitive impairment and trajectory of cognitive function over time in women with breast cancer, who received adjuv...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
화학요법관련 인지기능장애이란 무엇인가? | 그러나 화학요법을 받은 환자들은 갑작스러운 폐경이나, 성기능저하, 인지장애, 골다공증과 같은 이차적인 건강문제에 노출된다[3,4]. 이 중 화학요법관련 인지기능장애(chemotherapy-related cognitive impairment [CRCI])는 기억력과 주의집중력 저하를 주호소로 하는 증상으로 일반적으로 ‘chemo-brain’ 혹은 ‘chemofog’라고도 불린다. CRCI는 암 환자에게 유발되는 인지장애 중 대표적인 문제로 특히유방암환자에게빈번하게나타나는것으로알려져있다[5-7]. | |
화학요법으로 인해 유방암 환자에게 발생할 수 있는 문제는 무엇인가? | 화학요법은 대부분 유방암 환자에게 적용되는 보조요법으로 유방암 환자의 재발률을 감소시키고 생존율을 놀라울 정도로 증가시켜왔다. 그러나 화학요법을 받은 환자들은 갑작스러운 폐경이나, 성기능저하, 인지장애, 골다공증과 같은 이차적인 건강문제에 노출된다[3,4]. 이 중 화학요법관련 인지기능장애(chemotherapy-related cognitive impairment [CRCI])는 기억력과 주의집중력 저하를 주호소로 하는 증상으로 일반적으로 ‘chemo-brain’ 혹은 ‘chemofog’라고도 불린다. | |
CRCI의 발생률은 어느정도인가? | CRCI의 발생률은 화학요법을 받는 유방암 환자의 16~61%에서 발생하는 것으로 보고되며[8-14], 이 가운데 17~35% 정도가 장기간 지속되는 중증 이상의 인지장애를 경험한다[5,14]. 주로 영향을 받는 인지기능 영역은 언어적 활동기억(verbal working memory), 정신 운동처리속도(psychomotor processing speed) 및 시공간 기억(visualspatial memory)으로 화학요법 종료 후 시작되어 어떤 경우 10년 이상 지속되기 때문에 치료종료 후 다시 예전의 삶에 적응해야 하는 유방암 환자들은 이로 인해 만성적인 기능저하와 심리적인 고통을 경험한다[6,15]. |
Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2011. Cancer Research and Treatment. 2014;46(2):109-123. http://dx.doi.org/10.4143/crt.2014.46.2.109
Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. Journal of Clinical Nursing. 2010;19(9-10):1362-1370. http://dx.doi.org/10.1111/j.1365-2702.2009.03006.x
Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12(4):279-287.
Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clinical Breast Cancer. 2002;3(Suppl 3):S84-S90.
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treatment Reviews. 2012;38(7):926-934. http://dx.doi.org/10.1016/j.ctrv.2012.05.002
Myers JS. Chemotherapy-related cognitive impairment: The breast cancer experience. Oncology Nursing Forum. 2012;39(1):E31-E40. http://dx.doi.org/10.1188/12.onf.e31-e40
Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: Considerations in selection of a control group. Journal of Clinical and Experimental Neuropsychology. 2013;35(4):435-444. http://dx.doi.org/10.1080/13803395.2013.781995
Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Supportive Care in Cancer. 2011;19(10):1647-1656. http://dx.doi.org/10.1007/s00520-010-0997-4
Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: A controlled comparison. Cancer. 2009;115(8):1776-1783. http://dx.doi.org/10.1002/cncr.24192
Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905-1913. http://dx.doi.org/10.1002/cncr.22610
Ouimet LA, Stewart A, Collins B, Schindler D, Bielajew C. Measuring neuropsychological change following breast cancer treatment: An analysis of statistical models. Journal of Clinical and Experimental Neuropsychology. 2009;31(1):73-89. http://dx.doi.org/10.1080/13803390801992725
Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal of the International Neuropsychological Society. 2009;15(6):951-962. http://dx.doi.org/10.1017/s1355617709990567
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292-2299. http://dx.doi.org/10.1002/cncr.20272
Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. International Review of Psychiatry. 2014;26(1):102-113. http://dx.doi.org/10.3109/09540261.2013.864260
Avisar A, River Y, Schiff E, Bar-Sela G, Steiner M, Ben-Arye E. Chemotherapy-related cognitive impairment: Does integrating complementary medicine have something to add? Review of the literature. Breast Cancer Research and Treatment. 2012;136(1):1-7. http://dx.doi.org/10.1007/s10549-012-2211-5
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology. 2007;25(25):3866-3870. http://dx.doi.org/10.1200/jco.2007.10.8639
Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. The Clinical Neuropsychologist. 2006;20(1):76-89. http://dx.doi.org/10.1080/138540491005875
Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncology Nursing Forum. 2007;34(5):997-1005. http://dx.doi.org/10.1188/07.onf.997-1005
Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: A controlled longitudinal study. Breast Cancer Research and Treatment. 2010;123(1):25-34. http://dx.doi.org/10.1007/s10549-009-0606-8
Wagner LI, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: Development of the functional assessment of cancer therapy-cognitive function instrument. The Journal of Supportive Oncology. 2009;7(6):W32-W39.
Chelune GJ, Naugle RI, Luders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: Practice effects and base-rate information. Neuropsychology. 1993;7(1):41-52. http://dx.doi.org/10.1037/0894-4105.7.1.41
Lezak MD, Howieson DB, Loring DW, Hannay J, Fischer JS. Neuropsychological assessment. 4th ed. New York, NY: Oxford University Press;2004.
Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. European Journal of Oncology Nursing. 2013;17(2):236-241. http://dx.doi.org/10.1016/j.ejon.2012.06.002
Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Supportive Care in Cancer. 2012;20(7):1361-1375. http://dx.doi.org/10.1007/s00520-012-1445-4
Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33-50. http://dx.doi.org/10.1016/j.cortex.2014.01.010
Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology. 2009;18(2):134-143. http://dx.doi.org/10.1002/pon.1379
Myers JS, Teel C. Oncology nurses' awareness of cognitive impairment secondary to chemotherapy. Clinical Journal of Oncology Nursing. 2008;12(5):725-729. http://dx.doi.org/10.1188/08.cjon.725-729
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.